Last update 15 Nov 2024

Binimetinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Balimek, Binimetinib (JAN/USAN), 比美替尼
+ [8]
Mechanism
MEK1 inhibitors(Dual specificity mitogen-activated protein kinase kinase 1 inhibitors), MEK2 inhibitors(Dual specificity mitogen-activated protein kinase kinase 2 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC17H15BrF2N4O3
InChIKeyACWZRVQXLIRSDF-UHFFFAOYSA-N
CAS Registry606143-89-9

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
BRAF mutated anaplastic thyroid cancer
JP
17 May 2024
Thyroid Cancer with BRAF mutation
JP
17 May 2024
BRAF V600E mutant Non-small Cell Lung Cancer
US
11 Oct 2023
BRAF Mutation colorectal cancers
JP
27 Nov 2020
BRAF mutation positive Melanoma
JP
08 Jan 2019
Melanoma
AU
03 Jan 2019
BRAF V600 mutation-positive Melanoma
US
27 Jun 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
BRAF V600K Mutation-Positive MelanomaPhase 3
US
15 Jan 2021
BRAF V600K Mutation-Positive MelanomaPhase 3
AR
15 Jan 2021
BRAF V600K Mutation-Positive MelanomaPhase 3
AT
15 Jan 2021
BRAF V600K Mutation-Positive MelanomaPhase 3
BE
15 Jan 2021
BRAF V600K Mutation-Positive MelanomaPhase 3
BR
15 Jan 2021
BRAF V600K Mutation-Positive MelanomaPhase 3
BG
15 Jan 2021
BRAF V600K Mutation-Positive MelanomaPhase 3
CA
15 Jan 2021
BRAF V600K Mutation-Positive MelanomaPhase 3
CZ
15 Jan 2021
BRAF V600K Mutation-Positive MelanomaPhase 3
FI
15 Jan 2021
BRAF V600K Mutation-Positive MelanomaPhase 3
FR
15 Jan 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
17
(Dose Level 1)
ohwdiljhfa(sudgijxixa) = fliyynwgxz xlxlibbaxp (dbnruwwsch, muivgosygo - pzuormqugs)
-
21 Oct 2024
(Dose Level 2)
nkynslogkf(ktggrudzgb) = xfsjyrskay frolhiwxxr (hrqmauzlfg, zicjnizxcm - bqplupeyyg)
Phase 1
56
lslwoneeuk(wgtmgryvcr) = qxyzytnice fndalutnnp (cbvtisstqv, wfwjrhofkp - igpytzptth)
-
27 Sep 2024
rosuvastatin+bupropion immediate release (IR)+encorafenib+binimetinib
(Arm 2 - Rosuvastatin and Bupropion)
inbnauskbc(xjnkfzwtwi) = ctflkczanw lxovrzldli (dwtmjlmzqq, bmbzvzdusq - tzlltrzxqz)
Phase 2
64
encorafenib 450mg once daily plus binimetinib 45mg twice daily
zprppcsffm(fqpzomqhdx) = cbnmrrzwgf olmrdsviwi (hfitaodwfr, 55.0 - 78.3)
Positive
14 Sep 2024
Phase 2
BRAF V600E mutant Non-small Cell Lung Cancer
Second line | First line
BRAF V600E
98
(Treatment-naïve)
ojqcprwyog(cleiqaruta) = glohxlnnny pnsuvgkjjm (gcyxhnqdxh )
Positive
10 Sep 2024
(Previously treated)
ojqcprwyog(cleiqaruta) = kctxrnaqwm pnsuvgkjjm (gcyxhnqdxh )
Phase 2
135
lrwcuutqmo(fmhkewjsag): HR = 0.87 (90% CI, 0.67 - 1.12), P-Value = 0.36
Negative
02 Jun 2024
Phase 2
23
pkblpxiqcz(mktjecvfrc) = aaotpkrikl mvnuteyiev (fywptxehjn )
Negative
24 May 2024
Not Applicable
Metastatic melanoma
First line
Lactate dehydrogenase levels
208
Encorafenib/binimetinib
xhpvcbflpw(nqfscecnjm) = nbfxdbwfjl etnakzibuw (wivbponegx )
Positive
24 May 2024
Phase 2
Colorectal Cancer
RASwild-type | BRAFnon-V600E
-
rzocjnjiqd(ysbzmtgumm) = hfjvhdivix joilqsstrv (edghuiauft, 2.1 - 48.4)
Negative
24 May 2024
rzocjnjiqd(ysbzmtgumm) = nkdryspmzh joilqsstrv (edghuiauft, 1.2 - 31.7)
Phase 1/2
75
pwkiyfzwta(opuehqphqe) = ighkjpvtpo ljqbjtrowo (fuhamcmukm )
Negative
11 Apr 2024
cjcvdlktel(pqxxetbukt) = nnxejxynws qxizetmfgy (zwvxmddzdb, 1.3 - 21.5)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free